Agenus (AGEN) Amortization of Deferred Charges (2014 - 2026)
Agenus' (AGEN) quarterly Amortization of Deferred Charges came in at $14.5 million in Q1 2026, up 14.81% year-on-year from $12.6 million in Q1 2025, and down 8.08% quarter-over-quarter from $15.8 million in Q4 2025.
Agenus (AGEN) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Agenus' Amortization of Deferred Charges history runs 13 years deep, the most recent figure standing at $14.5 million for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 14.81% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $56.3 million, a 44.32% decrease from a year earlier, with the FY2025 full-year figure at $54.4 million, down 53.9% from the prior year.
- Amortization of Deferred Charges eased to $14.5 million in Q1 2026 per AGEN's latest filing, from $15.8 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $44.6 million in Q4 2023 and bottomed at $12.6 million in Q1 2025.
- The 5-year median for Amortization of Deferred Charges is $17.3 million (2023), against an average of $20.6 million.
- Across the five-year window, Amortization of Deferred Charges surged 143.23% in 2023 and slumped 64.13% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $18.3 million in 2022, then jumped by 143.23% to $44.6 million in 2023, then sank by 53.7% to $20.6 million in 2024, then slipped by 23.56% to $15.8 million in 2025, then slipped by 8.08% to $14.5 million in 2026.
- Per Business Quant, the three latest AGEN Amortization of Deferred Charges figures stand at $14.5 million (Q1 2026), $15.8 million (Q4 2025), and $13.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Agenus | 230.70 Mn | 195.70 Mn | 33.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.50 Mn |
| Mar 31, 2026 | 14.50 Mn |
| Dec 31, 2025 | 15.77 Mn |
| Dec 31, 2025 | 15.77 Mn |
| Sep 30, 2025 | 12.99 Mn |
| Sep 30, 2025 | 12.99 Mn |
| Jun 30, 2025 | 13.05 Mn |
| Jun 30, 2025 | 13.05 Mn |
| Mar 31, 2025 | 12.63 Mn |
| Mar 31, 2025 | 12.63 Mn |
| Dec 31, 2024 | 20.64 Mn |
| Dec 31, 2024 | 20.64 Mn |
| Sep 30, 2024 | 36.20 Mn |
| Sep 30, 2024 | 36.20 Mn |
| Jun 30, 2024 | 31.67 Mn |
| Jun 30, 2024 | 31.67 Mn |
| Mar 31, 2024 | 29.60 Mn |
| Mar 31, 2024 | 29.60 Mn |
| Dec 31, 2023 | 44.57 Mn |
| Dec 31, 2023 | 44.57 Mn |